A Violaceous Mass of the Chest: An Unsuspected Diagnosis of Primary Ewing Sarcoma
Main Article Content
Keywords
Ewing Sarcoma, Primary Ewing Sarcoma, Cutaneous Ewing Sarcoma, Primary Cutaneous Ewing Sarcoma
Abstract
Ewing Sarcoma is the second most common primary bone cancer. To date, only a few cases of primary cutaneous Ewing Sarcoma have been published. We present a unique case of primary cutaneous Ewing Sarcoma, which presented as a blue to violaceous mass on a young woman’s chest. The lesion clinically did not align with previous reports of primary cutaneous Ewing Sarcoma but pathology and immunohistochemical stains confirmed the diagnosis. Because primary cutaneous Ewing Sarcoma may masquerade as benign tumors, dermatologists must be suspicious of otherwise benign looking tumors.
References
2. Ozaki T. Diagnosis and treatment of Ewing sarcoma of the bone: a review article. Journal of Orthopaedic Science. 2015;20(2):250-263. doi:10.1007/s00776-014-0687-z
3. Oliveira Filho, Jayme de, et al. “Primary Cutaneous Ewing Sarcoma--Case Report.” Anais Brasileiros De Dermatologia, Sociedade Brasileira De Dermatologia, 2014, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4056713/.
4. Riggi N, Stamenkovic I. The Biology of Ewing sarcoma. Cancer Letters. 2007;254(1):1-10. doi:10.1016/j.canlet.2006.12.009
5. Lessnick SL, Ladanyi M. Molecular Pathogenesis of Ewing Sarcoma: New Therapeutic and Transcriptional Targets. Annual Review of Pathology: Mechanisms of Disease. 2012;7(1):145-159. doi:10.1146/annurev-pathol-011110-130237
6. Biermann JS, Chow W, Reed DR, et al. NCCN Guidelines Insights: Bone Cancer, Version 2.2017. Journal of the National Comprehensive Cancer Network. 2017;15(2):155-167. doi:10.6004/jnccn.2017.0017
7. Durer S, Shaikh H. Cancer, Ewing Sarcoma. PubMed. Published 2020. https://www.ncbi.nlm.nih.gov/books/NBK559183/
8. Grier HE, Krailo MD, Tarbell NJ, et al. Addition of Ifosfamide and Etoposide to Standard Chemotherapy for Ewing’s Sarcoma and Primitive Neuroectodermal Tumor of Bone. New England Journal of Medicine. 2003;348(8):694-701. doi:10.1056/nejmoa020890
9. Paulussen M, Craft AW, Lewis I, et al. Results of the EICESS-92 Study: two randomized trials of Ewing’s sarcoma treatment--cyclophosphamide compared with ifosfamide in standard-risk patients and assessment of benefit of etoposide added to standard treatment in high-risk patients. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2008;26(27):4385-4393. doi:10.1200/JCO.2008.16.5720
10. Kolb EA, Kushner BH, Gorlick R, et al. Long-Term Event-Free Survival After Intensive Chemotherapy for Ewing’s Family of Tumors in Children and Young Adults. Journal of Clinical Oncology. 2003;21(18):3423-3430. doi:10.1200/jco.2003.10.033
11. Haeusler J, Ranft A, Boelling T, et al. The value of local treatment in patients with primary, disseminated, multifocal Ewing sarcoma (PDMES). Cancer. 2010;116(2):443-450. doi:10.1002/cncr.24740
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.
Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.
Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.